β-Glucogallin

β-Glucogallin is an orally active and selective aldose reductase (AKR1B1) inhibitor with an IC₅₀ value of 58 μM when using Glyceraldehyde (HY-128748) as AKR1B1 substrate. β-Glucogallin reduces ROS, PDGF, RAGE, and NF-κB. β-Glucogallin increases SOD. β-Glucogallin has antioxidant and hepatoprotective effects. β-Glucogallin can be used in retinal research^{[1][2][3][4][5]}. IC50 & Target:IC50: 58 μM (AKR1B1) when using Glyceraldehyde (HY-128748) as AKR1B1 substrate In Vitro: β-Glucogallin (100 μM; 2 h) can reduce Methylglyoxal-induced oxidative stress in human retinal epithelial cells ARPE-19, decreasing intracellular ROS levels^[1].
β-Glucoside inhibits AKR1B1 with Glyceraldehyde (HY-128748) as substrate, with an IC₅₀ value of 58 μM^[2].
β-Glucogallin (30 μM; 72 h) can inhibit sorbitol accumulation under hyperglycemic conditions in a transgenic mouse lens organ culture model, with an inhibition rate of 73%^[2].
β-Glucogallin can inhibit the activity of AKR1B1 and prevent Sorbitol (HY-B0400) accumulation in RAW264.7 murine macrophage cells, with an inhibition rate of approximately 50%^[3].
In Vivo: β-Glucogallin (300-1200 mg/kg; p.o.; once daily; 10 days) improves Carbon tetrachloride (HY-Y0298)-induced hepatotoxicity in female Wistar rats^[4].